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Abstract
Background: Cytokines are known to be key players in dry eye syndrome (DES) and Sjogren’s syndrome (SS)
pathogenesis. In this study we compared single nucleotide polymorphism (SNP) variations in genes encoding
cytokine levels among SS and DES patients in Israel.
Methods: We recruited 180 subjects, 82 with SS and 98 with DES. Using a candidate gene approach and allele-
specific PCR technique for genotyping, proportions of risk alleles in Tumor Necrosis Factor α (TNFα) (rs1800629),
IinterLeukin-10 (IL-10) (rs1800896) and TNFAIP3 (rs2230926) SNPs were compared between study groups.
Results: Allelic distribution was found very similar to Caucasian (CEU – Utah residents with Northern and Western
European roots) population distributions in these SNPs. While none of the SNPs’ variants were significantly
associated with SS or DES in a recessive model, in an additive model the TNFα G risk allele was found higher
among SS patients compared to DES (Homozygote-G: 84.2% vs. 70.8%; Heterozygote: 26.9% vs. 11.2%, respectively,
p = 0.02). After adjustment for age, gender and ethnicity, these variants weren’t associated with SS. Genetic scoring
reveals that SS patients are more likely to present variants of all three SNPs than DES subjects.
Conclusions: This is the first study evaluating these SNP variations among both patients with DES and patients
with SS. We found the allelic distribution in each SNP to be very similar to that found in healthy Caucasian
populations presented in the HapMap project. We found the TNFα allele significantly associated with DES for
homozygotes, and associated with SS for heterozygotes in the additive model.
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Background
Dry eye syndrome (DES), a chronic inflammation of the
ocular surface with potential damage to the external eye,
may be one of the clinical manifestations of Sjogren’s
syndrome (SS), a systemic Autoimmune Disease
(AID) [1, 2]. SS is characterized mainly by severe dry
eyes (xerophthalmia) and dry mouth (xerostomia),
and can be primary (pSS) or secondary (sSS) to other
AID [3, 4]. Both DES and SS are known to be associated
with elevated cytokine levels in the serum, including
inflammatory cytokines such as IFN-γ, TNFα, IL-1, IL-6,
IL-8, IL-12, IL-17 and IL-1β as well as anti-inflammatory
cytokines as TGF-β, IL-4 and IL-10 [5–9].
Familial aggregation, candidate gene studies and Gen-
ome Wide Association (GWA) studies have suggested a
hereditary component in SS establishment [10–13].
However, there is no consensus regarding the role of
genes encoding cytokines in the pathogenesis of SS and
DES. Several studies have found polymorphisms in genes
encoding cytokine levels or other aspects of immune
pathways to be associated with SS [10, 12]. Single
nucleotide polymorphisms (SNP) in the TNFα and IL-10
genes showed very strong genotype association with pSS
subjects in comparison to DES subjects and controls,
supporting the hypothesis these genes are main factors
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in SS immunogenetics [14–16]. However, no association
was found in IL10 promoter polymorphism with suscep-
tibility to pSS [17]. The gene TNFAIP3 (rs2230926G)
(A20) was found to be highly associated with pSS pro-
gression [8, 18, 19].
In this study we wished to compare SNPs’ variations in
three genes related to the immune pathway; IL10
(rs1800896), TNFα (rs1800629) and TNFAIP3 (rs2230926),
between established SS and DES Jewish patients using a
candidate gene approach.
Methods
Study population
Recruitment was performed using combined strategies:
The first involved approaching SS patients consulting oph-
thalmology, oral medicine, rheumatology and hematology
clinics in Hadassah Medical Center, and DES patients
consulting ophthalmology clinics with a complaint of dry
eyes. The second recruitment method for DES cases was
via an advertisement placed in Hadassah clinics, local
newspapers and emails to Hadassah employees, addressing
anyone suffering from dry eyes and willing to participate in
the study.
Diagnosis of DES was done by a cornea specialist, or by
self-reported symptoms. Later, both groups were evaluated
with the Schirmer I test (without anesthesia) with score of
< 5mm in 5min and the Ocular Surface Disease Index
(OSDI) questionnaire (with a minimal score > 25) [20] in
order to create a common basis for comparison, and also
to validate the self-report based diagnoses. The SS
diagnosis was based on 4 out of 6 criteria of the US-Euro
classification [21] and was done by a rheumatologist, oral
surgeon or cornea specialist. Patients fulfilling the
inclusion criteria were recruited to the study and DNA
was extracted from their peripheral blood using the salting
out method. Overall 180 participants, 82 with verified SS
and 98 with DES, entered the study. All participants
signed an informed consent form. Blood samples and data
were coded anonymously.
Genotyping
The polymorphisms of IL10 (rs1800896), TNFα
(rs1800629) and TNFAIP3 (rs2230926) were detected
using an allele-specific polymerase chain reaction (PCR)
assay. DNA was isolated from venous blood, and
purified in the “salting out” method as described by the
Manual Archive Pure DNA Purification Kit (5 Prime,
USA). The quality and the quantity of DNA were deter-
mined by NanoDrop™ 8000 Spectrophotometric analysis.
All samples of SS and DES patients were diluted with
Deuterium Depleted Water (DDW) in a final concentra-
tion of 10 ng/30 μl. Bi-allelic discrimination was achieved
through the competitive binding of two allele-specific
forward primers, each with a unique tail sequence that
corresponded with two universal fluorescence resonant
energy transfer (FRET) cassettes. The assay also
contained one reverse primer, and once the reactions
were completed and the resulting fluorescence intensity
has been measured, the raw data was interpreted to
enable genotypes for each DNA sample. For quality
control of this assay, inter and intra plating duplicates of
about 4% of the samples were sent for genotyping (2
negative controls in each plate), and the result of only
one sample of each pair was entered to the final data
analysis. Genotyping was performed in “LGC Genomics”
laboratory in the UK.
Statistical analysis
Parameters such as age category, gender, ethnicity and
the main manifestation of SS disease were presented as
proportions. The risk alleles of each SNP were chosen
according to current literature and were found to be
associated to SS in former studies [14–16, 18, 19]. The
prevalence of SNP variations was calculated first in a
recessive model, in which the frequency of each allele of
the tested SNPs was compared between the two study
groups, and then in an additive model, which demon-
strated the genotype distribution of homozygotes and
heterozygotes for alleles of each SNP in SS and DES
groups.
Power calculation of each tested SNP showed that for
the given sample size, for the risk allele frequency in
Caucasian populations with α = 0.05 and to achieve
power (1-β) of 80%, the detectable ORs in the recessive
model are: 4.5 for the TNFα, 2.5 for the IL-10 and 6.0
for the TNFAIP3. In the additive model, by the heterozy-
gote frequency, in order to reach power of 80% the
detectable ORs are: 2.4, 2.4 and 4.1, respectively.
The comparison of these categorical parameters in the
two models was done by a χ2 test. A validation of allelic
frequencies were performed, using an applicable data
from HAP-MAP project, with the expected distributions
among CEU (Utah residents with Northern and Western
European roots) Caucasian populations [22]. A genetic
score was calculated using the sum of SNPs’ polymor-
phisms, and the relation of this score to the tested
disease was analyzed using χ2. A logistic regression
model, based on additive model and adjusted for con-
founders, was used in order to demonstrate the OR (odds
ratio) for SS compared to DES for each tested SNP. Statis-
tical analysis was done using SPSS 23.0 software (Chicago,
IL 60606–6307), with α = 0.05, and power calculation was
done using WinPepi 11.63 software.
Results
A total of 180 patients entered this study, with a mean age
[and SD] of 56.7 [13.1] years for the SS group and 50.0
[15.2] for the DES group and overall age range of 19–86
Ben-Eli et al. Journal of Inflammation            (2019) 16:6 Page 2 of 6
(Table 1). As expected, most of the study participants were
women in both the SS and the DES groups (N = 75; 91.5%
and N = 68; 69.3%, respectively). Eastern European ances-
try was the most common ethnicity (39% in SS and 56.1%
in DES). The main clinical manifestations among SS pa-
tients had a fairly even distribution, the chief complaint
being dry eyes among 26.6% of patients, dry mouth among
34.2%, and joint pain among 39.1% (Table 1). Although
division to SS subgroups according to disease’ manifesta-
tions was presented, aa comparison of the allelic distribu-
tion of these subgroups to DES group was not performed
due to a relatively small numbers of patients with different
allelic distribution within these subgroups. Therefore, the
genotyping analysis considered all patients with SS as one
group.
Genotyping tests produced identical results for all
duplicate samples. Table 2 lists the frequencies of the
various alleles in a recessive model, in which the risk
allele was counted if it was present either once or twice
in the same individual in the genotype for each SNP.
The frequency of having two risk alleles in the tested
SNPs was found to be higher in SS group compared
to DES, but the difference was not significant. Risk
allele G in SNPs rs1800629 was found to be more
frequent among SS patients (84.2%) compared to DES
patients (70.3%) (P = 0.56). In rs1800896-A the fre-
quency of the risk allele was 62.1% in SS and 57.2%
in DES (P = 0.23), and in rs2230926-G the frequency
of risk allele was lower in the SS group (5.9%) than
the DES (8.4%) (P = 0.54). When comparing these
alleles’ frequencies distribution in the recessive model to
a control CEU (Caucasian) population, as presented in the
International HAP-MAP project, only minor differences
were noted.
Table 3 demonstrates the polymorphism in an additive
model, giving greater weight to the risk allele homozy-
gote relative to the heterozygote or homozygote of the
other allele. The rs1800629-G allele was found to be
significantly associated with DES compared to SS for
homozygotes of the risk allele (84.7 and 70.8% respect-
ively) (P = 0.02). The frequency of homozygote and
heterozygote rs1800896-A risk allele was higher in SS
patients (39.1 and 44.0% respectively) than DES patients
(35.7 and 42.9% respectively), but the difference was not
statically significant (P = 0.64). The SNP variation distri-
bution was found to be similar for the rs2230926-G
allele among SS and DES for homozygote and for het-
erozygote to the risk allele. When comparing these al-
leles’ frequencies distribution in the additive model to a
control CEU (Caucasian) population, as presented in the
International HAP-MAP project, only minor differences
were noted in all tested SNPs.
A genetic score (Table 4) was constructed by summing
the prevalence of 1, 2 or 3 SNPs’ variations in each
individual with SS or DES. These results show that more
patients with DES carry 1 or 2 of the risk alleles of the
tested SNPs than SS patients (58.3% vs 41.7 and 54.5%
vs 45.5%, respectively), while variation in three SNPs
was more common in SS than DES (58.3% vs 41.7), but
the findings were not statistically significant (P = 0.60).
Furthermore, no association was found among these
three tested SNP’s in genetic scoring.
The logistic regression model (Table 5) revealed that
SS is associated with female gender (OR = 3.62; 95% CI:
1.36–9.62), younger age (OR = 0.96; 95% CI: 0.93–0.98)
and Eastern Europe ethnicity (OR = 0.39; 95% CI: 0.19–
0.78 vs other). None of the three tested SNPs was found
to be associated with SS in the logistic regression model.
Discussion
Our study is the first to evaluate all these three SNP
variations among both patients with DES and patients
with SS. We found the allelic distribution in each SNP
among patients with SS and DES very similar to that
found in Caucasian populations (CEU) presented in the
HapMap project, which validates our findings. The
TNFα(rs1800629-G) allele was found to be significantly
associated with DES for homozygotes, and associates with
SS for heterozygotes in the additive model. Our study
reveals, using genetic scoring, that SS patients are more
likely to have all these three SNPs’ variations than DES
patients. Furthermore, females were found to have a
higher genetic risk for SS compared to DES.
Several studies have found an association between SS
and polymorphisms in genes encoding cytokines TNFα
(rs1800629), IL10 (rs1800896) and TNFAIP3 (rs2230926),
but have not found correlation to DES [14–16, 18]. Yet, in
other works, this association was not shown [17, 23]. In
Table 1 Characteristics of study population
SS* (n = 82) DES† (n = 98)
Mean age [SD‡] 56.7 [13.1] 50.0 [15.2]
Age range 20–86 19–83
Female gender: n (%) 75 (91.5) 68 (69.3)
Ethnicity: n (%)
Eastern Europe 32 (39) 55 (56.1)
West Asia 20 (24.4) 16 (16.3)
North Africa 19 (23.1) 10 (10.2)
Israel 6 (7.3) 8 (8.1)
Mixed 5 (6.1) 9 (9.2)
SS manifestation: n (%)
Eyes 22 (26.6) NA
Mouth 28 (34.2) NA
Joints 32 (39.1) NA
* - ss (Sjogren’s Syndrome); † − DES (Dry Eye Syndrome); ‡ - SD
(standard deviation)
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our study we compared the allelic frequency of the risk
allele in these three SNPs among SS patients vs. those with
DES. The allelic distribution in each SNP was very similar
to that found in Caucasian populations (CEU). We found
that only the TNFα (rs1800629-G) allele was significantly
associated with DES for homozygotes, and associates with
SS for heterozygotes in the additive model. The TNFα
gene promoter is known to be associated with TNFα
protein levels, inflammation, outcome of infection,
susceptibility to autoimmune diseases such as SS, and also
with the most serious complication associated with SS, i.e.
non-Hodgkin lymphoma [14].
The results of the genetic scoring demonstrate that
individuals with all three SNP variations tested in this
study have a higher likelihood of having SS than DES.
As expected, female gender has the strongest effect on
the risk of SS, while Eastern European ethnicity had a
protective effect on the disease. When adjusting for
possible confounders, these SNPs were not found to be
risk factors for SS.
Our study was limited by a small sample size which
resulted in limited power, and also by the fact that the
comparison was only between SS and DES subjects, who
may have a similar immune system hyperactivity charac-
teristics. Additionally, the study did not include a healthy
control group.
Using a candidate gene approach, IL10 (rs1800896-A)
and TNFAIP3 (rs2230926-G) were not found to be
significantly more strongly associated with SS compared
to DES. The TNFα (rs1800629-G) SNP was found to be
associated with SS and not with DES in an additive
model. These results emphasize the need for further
studies comparing between SS, DES and healthy con-
trols, and studies on larger populations and different
ethnic groups. Further research should include healthy
control subjects, a larger number of subjects within SS
subgroups and should analyze protein levels for the
Table 2 Distribution of SNP variations among study participants - Additive model
SNP Risk Allele SSa (n = 82) n (%) DESb (n = 98) n (%) P (χ2) CEUc Freq. (HapMap)
TNFα (rs1800629) G Homozygote G 58 (70.8) 83 (84.7) 67.3
Heterozygote 22 (26.9) 11 (11.2) 31
Homozygote A 1 (1.3) 2 (2.1) 1.8
0.02
IL10 (rs1800896) A Homozygote G 13 (15.9) 21 (21.4) 27.4
Heterozygote 36 (44.0) 42 (42.9) 51.3
Homozygote A 32 (39.1) 35 (35.7) 21.2
0.64
TNFAIP3 (rs2230926) G Homozygote T 73 (89.2) 85 (86.7) 94.7
Heterozygote 8 (9.8) 10 (10.3) 5.3
Homozygote G 0 0 0
0.54
a- ss (Sjogren’s Syndrome); b − DES (Dry Eye Syndrome)
c − CEU (C): Utah residents with Northern and Western European ancestry from the CEPH collection. Data is available at Hapmap
Table 3 Distribution of SNP variations among study participants
- Recessive model
SNP Risk
Allele
Allele SSa
(n = 82) %
DESb
(n = 98) %
P (χ2) CEUc
Freq.
(HapMap)
TNFα
(rs1800629)
G
G Allele 84.2 70.3 82.7
A Allele 15.8 29.7 17.3
0.56
IL10
(rs1800896)
A
G Allele 37.9 42.8 53.1
A Allele 62.1 57.2 46.9
0.23
TNFAIP3
(rs2230926)
G
T Allele 94.1 91.6 97.3
G Allele 5.9 8.4 2.7
0.54
a - ss (Sjogren’s Syndrome); b −DES (Dry Eye Syndrome)
c − CEU (C): Utah residents with Northern and Western European ancestry from
the CEPH collection. Data is available at Hapmap
Table 4 Genetic scoring for SNP variations
SNP SSa (n = 82) n (%) DESb (n = 98) n (%) Total n (%) P (χ2)
1 SNP 15 (41.7) 21 (58.3) 36 (100)
2 SNP 60 (45.5) 72 (54.5) 132 (100)
3 SNP 7 (58.3) 5 (41.7) 12 (100) 0.60
a - ss (Sjogren’s Syndrome); b −DES (Dry Eye Syndrome)
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three cytokines in the patients’ serum. Moreover, further
exploration of other SNPs’ variations related to the
immune pathway, which may play a role in SS establish-
ment, is needed. SS is a non-common disease and this
study demonstrates the importance of consortia and
collaborative studies in order to study genetic suscepti-
bility to autoimmune diseases.
Conclusions
In this study we explored the association between three
SNP’s of genes encoding cytokines and relate to the
immune pathway and between common disease, DES, as
well as SS. The allelic distribution in each SNP was
found to be very similar to that found in healthy Cauca-
sian populations presented in the HapMap project.
TNFα allele was found to be significantly associates with
DES for homozygotes, and associates with SS for hetero-
zygotes in the additive model. The IL-10 allele and
TNFAIP3 allele weren’t found to be significantly associ-
ated with SS nor DES. Further research will help reveal-
ing additional alleles that can be associated with these
syndromes leading to a better understanding it’s immune
pathway.
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